Why the study?
Does early post-transplant Torquetenovirus viremia predict cytomegalovirus reactivation in liver or kidney transplant recipients?
Population
280 liver or kidney transplant recipients on different immunosuppressive drug regimens
Design
Cohort
Follow-up
One-year
Authors
Loading...
Early TTV monitoring may refine CMV risk stratification post-transplant; leaves open prospective validation before guiding immunosuppression.
Does early post-transplant Torquetenovirus viremia predict cytomegalovirus reactivation in liver or kidney transplant recipients?
Early post-transplant TTV viremia may serve as a useful biomarker to predict CMV reactivation in solid organ transplant recipients.
Maggi et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: